A study published in the New England Journal of Medicine has analysed the effectiveness of the antiviral drug Paxlovid after implantation of the omicron variant. The relative risk of severe disease decreased markedly in patients over 65 years of age, both vaccinated and unvaccinated. No differences were found in those under 65 years of age.
Roger Paredes - paxlovid
Roger Paredes
Head of the Infectious Diseases Service at the Germans Trias i Pujol Hospital and senior researcher at the AIDS Research Institute (IrsiCaixa).
This is a very important study because until now the data on protection of hospitalisations with Paxlovid had been obtained in patients infected with pre-omicron variants and mostly in unvaccinated patients, so there were doubts as to whether Paxlovid would still be useful in vaccinated people. This study shows that, even in these patients, early treatment prevents severe clinical forms, as long as the patients are at high risk of hospitalisation (over 65 years of age, etc.).
- Research article
- Peer reviewed
- People
